Publication date: Sep 11, 2019
First results from the National Lung Matrix Trial (NLMT), the largest global precision medicine trial in non-small cell lung cancer (NSCLC), showed that the probability of success with respect to achieving a clinically relevant objective response rate (ORR) in patients treated with crizotinib was very high for those with disease characterized by ROS1 gene fusions and a MET exon 14-skipping mutation – but the response was not as evident in those with NSCLC characterized by a MET amplification.
The NLMT (ClinicalTrials. gov Identifier: NCT02664935) is a multidrug, phase 2 study of adaptive design consisting of multiple single arms, each evaluating targeted therapy in a cohort of adult patients with NSCLC characterized by the presence of 1 or more specific actionable molecular alteration(s) as detected by a specific targeted sequencing panel.
Interim efficacy analyses conducted in other study cohorts, such as patients with disease characterized by an NF1 mutation receiving the MEK inhibitor selumetinib, in combination with docetaxel (16 individuals); and the cohort of patients with NSCLC characterized by the double LKB1/KRAS mutation who were treated with the mTOR inhibitor, vistusertib (23 individuals); met the criteria for study continuation.
However, the arm of the study evaluating vistusertib in the cohort of patients with disease characterized by a single mutation in LKB1 was closed following an interim analysis of efficacy.
|disease||MESH||non-small cell lung cancer|
|pathway||BSID||Non-small cell lung cancer|
- Precision Medicine Trials and Molecular Testing Guidelines Expand to Reach More Patients
- Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
- Umbrella and basket trials in oncology: ethical challenges.
- Next-generation sequencing for tumor mutation quantification using liquid biopsies.